Alert detail
FDA Approval: REXTOVY (NALOXONE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer
Policy ID: FDA-NDA208969Specialty: Infectious DiseaseAdded: 6/18/2026Effective: 2023-03-07federal register
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.